A linker is a short molecular bridge that connects two functional components in a biological or pharmaceutical system. In biotechnology and drug design, linkers join proteins to other proteins, or antibodies to toxic drug payloads, controlling how the combined molecule behaves in the body. Though small, linkers play an outsized role in determining whether a therapeutic works safely or fails entirely.
How Linkers Work in Fusion Proteins
In their simplest form, linkers are short chains of amino acids that connect two protein domains within a single molecule. Nature uses them constantly: most multi-domain proteins have built-in linker sequences that keep neighboring domains from interfering with each other. These natural linkers range from 2 to 31 amino acids in length, fine-tuned so they don’t constrain the shape or function of the domains they connect.
When scientists engineer fusion proteins in the lab, they design artificial linkers to join two proteins that don’t naturally connect. The choice of linker sequence matters enormously. Glycine-rich linkers are flexible, acting like a loose tether that lets each protein domain move and fold independently. This flexibility is especially useful when the two proteins interact weakly or transiently, because the linker holds them close without locking them into a fixed position. Rigid linkers, by contrast, keep the two domains at a set distance and prevent unwanted contact between them. Most natural linkers are actually rigid for this reason.
Beyond simply holding two pieces together, linkers can improve how much protein a cell produces, boost biological activity, and even change how long the molecule lasts in the body. Some linkers are designed to be cut apart inside living cells, releasing one domain from the other at a specific time and place. These are called cleavable linkers, and they’ve become central to one of the most important drug technologies in modern oncology.
Linkers in Antibody-Drug Conjugates
The highest-profile use of linker technology today is in antibody-drug conjugates, or ADCs. An ADC is a cancer therapy that pairs an antibody (which finds and binds to tumor cells) with a potent cell-killing drug (the “payload”). The linker is the chemical tether between them, and its design determines everything about the drug’s safety and effectiveness.
The linker has two contradictory jobs. It must remain completely stable in the bloodstream after injection so the toxic payload doesn’t detach and damage healthy tissue. But once the ADC reaches a tumor cell and gets pulled inside, the linker needs to release that payload so it can do its work. Getting this balance wrong in either direction means a drug that’s either too toxic or not effective enough.
ADCs undergo constant chemical transformation as they circulate through the body. The linker can be broken down, its chemical bonds can shift, and the payload can be metabolized, all before the drug reaches its target. Linker design directly shapes how long the ADC survives in circulation, how efficiently it releases its payload inside tumors, and how much collateral damage it causes along the way.
Cleavable vs. Non-Cleavable Linkers
There are two broad families of linkers used in ADCs, and the distinction between them is one of the most consequential choices in drug design.
Cleavable linkers contain a built-in chemical trigger that gets activated by conditions found inside tumor cells. More than 80% of clinically approved ADCs use this approach. The triggers exploit specific differences between the inside of a cancer cell and the bloodstream:
- Acid-sensitive triggers break apart in the low-pH environment inside cellular compartments. The interior of a cell’s recycling machinery sits at a pH of 4.8 to 6, compared to the neutral 7.4 of blood plasma, and certain chemical bonds (like hydrazones) snap under those acidic conditions.
- Enzyme-sensitive triggers use peptide sequences that get recognized and cut by enzymes concentrated inside tumor cells. Dipeptide linkers like valine-citrulline and valine-alanine are among the most widely used in approved ADCs.
- Reduction-sensitive triggers contain a chemical bond (a disulfide bridge) that gets broken by a molecule called glutathione, which exists at much higher concentrations inside cells than in blood plasma.
Non-cleavable linkers take the opposite approach. They contain no release trigger at all. Instead, the entire antibody must be broken down inside the cell before the payload is freed. Only one approved ADC, trastuzumab emtansine (Kadcyla), uses a non-cleavable linker. It connects the antibody to its payload using a stable chemical bridge called SMCC. The trade-off is that non-cleavable linkers tend to be more stable in circulation, reducing off-target toxicity, but they depend entirely on the cell’s ability to digest the whole antibody.
Linkers in Approved Cancer Drugs
The variety of linker designs across approved ADCs illustrates how much this single component shapes each drug’s profile. Brentuximab vedotin (Adcetris), approved in 2011 for certain lymphomas, uses a valine-alanine cleavable linker attached to the tubulin-disrupting payload MMAE. Several later drugs adopted the same valine-citrulline linker design, including enfortumab vedotin (Padcev) for bladder cancer and tisotumab vedotin (Tivdak) for cervical cancer.
Trastuzumab deruxtecan (Enhertu), one of the most commercially significant ADCs in oncology, uses a different cleavable linker based on a four-amino-acid peptide sequence. This design allows a notably high drug-to-antibody ratio of about 7.8 payload molecules per antibody, compared to 3 to 4 for most other ADCs. That higher loading is partly enabled by the linker’s properties.
Earlier ADCs like gemtuzumab ozogamicin (Mylotarg), first approved in 2000, used acid-sensitive hydrazone-based linkers. These proved less stable in circulation than enzyme-sensitive designs, contributing to safety concerns that temporarily pulled the drug from the market. The evolution from hydrazone linkers to peptide-based cleavable linkers reflects decades of learning about what makes a linker perform well in patients.
Why Solubility Matters in Linker Design
Many of the most potent cancer-killing payloads used in ADCs are extremely water-repellent. When you attach several of these greasy molecules to an antibody, the whole complex can clump together, lose stability, or get cleared from the bloodstream too quickly. The linker is the main tool engineers have to counteract this problem.
Adding water-attracting chemical groups to the linker, such as polyethylene glycol (PEG) chains, sugar molecules, or charged groups, shields the payload’s greasiness and keeps the ADC soluble. Loncastuximab tesirine (Zynlonta), for example, incorporates a PEG-containing linker partly for this reason. These hydrophilic linker modifications reduce aggregation, improve safety profiles, and allow drugs to carry higher payloads without becoming unstable.
Linker Length and Flexibility
In protein engineering, the physical dimensions of a linker directly affect how the connected domains behave. A linker that’s too short can force two protein domains into strained positions, preventing proper folding. One that’s too long may flop around excessively, reducing the efficiency of interactions between the domains. Researchers typically optimize linker length empirically for each specific application, testing multiple lengths to find the best performance.
Flexible glycine-rich linkers act as independent structural units, meaning they don’t interfere with the function of whichever proteins they connect. The fused proteins behave as though they’re separate molecules that happen to be tethered together, performing the combined function of both partners. Rigid linkers, often containing proline or alpha-helical sequences, are chosen when the spatial relationship between two domains needs to be fixed, preventing them from collapsing onto each other or interacting in unwanted ways.
In ADCs, linker length and flexibility also influence how accessible the cleavage site is to enzymes or chemical conditions inside the cell. A linker that buries its trigger deep within the antibody’s surface may resist cleavage even after the ADC reaches its target, reducing effectiveness. Spacing elements within the linker can position the trigger where cellular machinery can reach it.